Skip to main content
. 2017 Jul 1;31(13):1339–1353. doi: 10.1101/gad.298463.117

Figure 4.

Figure 4.

p53 restoration has a comparable therapeutic impact on p53-null and mutant lung tumors in vivo. (A) Representative hematoxylin and eosin-stained sections showing lung tumor burden. (B) Quantification of Ki67+ cells per tumor (immunohistochemistry) in null, R172H, and R270H mice after 6 d of treatment (vehicle: “p53 off”; tamoxifen: “p53 on”). (C) Illustrative data showing TUNEL staining (arrowheads) in lung tumor sections. Bar, 60 µm. (D) Quantification of TUNEL-positive cells per tumor 24 h after treatment. (B,D) Circles represent independent tumors, and average value per cohort ±SEM is shown (t-test). Three or more mice per cohort were analyzed. (E) Quantification of low- and high-grade tumor frequencies in null, R172H, and R270H mice treated for 6 d. A minimum of 68 tumors per cohort (from five or more mice) was analyzed. (F) Quantification of Ki67-positive cells per tumor (immunohistochemistry) in null, R172H, and R270H tumors 24 h after treatment with tamoxifen (p53 on) or tamoxifen and irradiation (p53 on + IR). Independent tumor values and average positivity per cohort ±SEM are shown. A minimum of three mice per cohort was used. (B,D,F) t-test. (E) Fischer's exact test. (ns) Nonsignificant; (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.